Company: SCLXW
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001193125-25-221022
Chunk: 125

Company: Scilex Holding Co
Filing Date: 2025-09-29
Form: 424B3
Chunk 125
---
received 15,000,000 shares of Datavault common stock with the remainder to be issued in a second tranche in the form of a pre-funded warrant to purchase Datavault common stock, subject to approval by
Datavault’s stockholders of, among other things, the issuance of Datavault shares to Scilex in excess of 19.99% of Datavault’s total pre-financing shares outstanding.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For
more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on
ZTlido including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba, including Full Prescribing Information, refer to www.gloperba.com.

About Scilex Holding Company

Scilex is an
innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and
cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to
advancing and improving patient outcomes. Scilex’s commercial

Page | 1

products include: (i) ZTlido (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and
Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB, a
potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or
without aura, in adults; and (iii) Gloperba, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel)
(“SEMDEXA” or “SP-102”), which is owned by Semn